Technical Analysis for TRDA - Entrada Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -3.93% | |
| NR7 | Range Contraction | -3.93% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 7 hours ago |
| Down 3% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Down 2 % | about 10 hours ago |
| Up 1% | about 10 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/10/2024
Entrada Therapeutics, Inc. Description
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Disease Medical Genetics Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Myotonic Dystrophy Genetic Genealogy Neuromuscular Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.44 |
| 52 Week Low | 10.735 |
| Average Volume | 80,275 |
| 200-Day Moving Average | 14.80 |
| 50-Day Moving Average | 13.38 |
| 20-Day Moving Average | 13.43 |
| 10-Day Moving Average | 13.09 |
| Average True Range | 0.81 |
| RSI (14) | 39.02 |
| ADX | 17.17 |
| +DI | 10.85 |
| -DI | 21.04 |
| Chandelier Exit (Long, 3 ATRs) | 12.09 |
| Chandelier Exit (Short, 3 ATRs) | 14.58 |
| Upper Bollinger Bands | 14.50 |
| Lower Bollinger Band | 12.36 |
| Percent B (%b) | -0.07 |
| BandWidth | 15.95 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.06 |
| MACD Histogram | -0.1267 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.32 | ||||
| Resistance 3 (R3) | 13.42 | 13.15 | 13.13 | ||
| Resistance 2 (R2) | 13.15 | 12.87 | 13.10 | 13.07 | |
| Resistance 1 (R1) | 12.69 | 12.70 | 12.56 | 12.59 | 13.01 |
| Pivot Point | 12.42 | 12.42 | 12.36 | 12.37 | 12.42 |
| Support 1 (S1) | 11.96 | 12.14 | 11.83 | 11.86 | 11.43 |
| Support 2 (S2) | 11.69 | 11.97 | 11.64 | 11.37 | |
| Support 3 (S3) | 11.23 | 11.69 | 11.31 | ||
| Support 4 (S4) | 11.13 |
